October 1, 2009 - Santa Clara, CA
Lumenis Inc., a global developer, manufacturer and seller of laser, light-based and radio-frequency devices for surgical, aesthetic, and ophthalmic applications, announced today the launch of the AcuPulse™ Fractional CO2 Laser System for aesthetic applications at the American Society of Dermatologic Surgery’s annual meeting in Phoenix this week.
“The AcuPulse™ now gives physicians an affordable and efficient solution to their Pulsed Fractional Skin Resurfacing needs” said Mr. Robert Mann, General Manager of Lumenis Global Aesthetics and Dermatology. “It has been well established that pulsed CO2 lasers are superior in the treatment of wrinkles, skin dyschromias, certain types of scars, and the Lumenis’ AcuPulse™ brings its SuperPulseTM technology with the unmatched fractional scanning excellence of the Lumenis portfolio to give physicians an excellent solution for their practice” added Mr. Mann.
"With the AcuPulse™ now available for Aesthetics, Lumenis will secure its leadership in the Fractional Laser market worldwide" commented Mr. Dov Ofer, Lumenis’ Chief Executive Officer. “There are many mid and low power fractional laser systems available in the market, but Lumenis’ AcuPulse™, with its SuperPulseTM capability, provides the lowest level of thermal damage with the same precision scanning technology already proven by its “big brother”, the UltraPulse®. This system will provide the best solution for physicians at this price in the market” added Mr. Ofer.
About the Business of Fractional Laser Treatments
“Ablative fractional laser skin treatments offer the happy median in the treatment of facial wrinkles. In the past, traditional fully ablative skin resurfacing provided superior results in the resolution of deep facial wrinkles, but patients had to endure several weeks of downtime. With ablative fractional laser treatments patients are offered significant wrinkle resolution with minimal downtime lasting only 4-7 days”, said Dr. E. Victor Ross, Director of the Laser and Cosmetic Dermatology Center of Scripps Health in San Diego, California. “Based on the clinical treatments, we expect histologies to show that the AcuPulse™, with its SuperPulseTM mode, ablates tissue in a mode similar to that of the UltraPulse®, which has proven itself a contributor toward excellent patient outcomes. We are excited to see an industry leader listening to the market and making a quality product available to meet the needs of more physicians.” said Dr. Girish Munavalli. Medical Director of the Dermatology, Laser, and Vein Specialists of the Carolinas in Charlotte, North Carolina.
About the AcuPulse™ CO2 Laser System
The AcuPulse™ Fractional CO2 Laser System is the only laser of its kind providing true SuperPulseTM technology, as well as Continuous Wave (CW) technology, combined with the benefits of the legendary scanning heritage within the Lumenis CO2 Product line. With the SuperPulseTM technology Lumenis provides another segment in their pulsed CO2 Fractional Laser Systems other than the UltraPulse®, already proven to be one of the most effective laser systems for fractional laser treatments of the skin. With less thermal damage per treatment spot than standard CW lasers, the AcuPulse™ with SuperPulseTM technology is poised to be a significant player in the mid-price point fractional laser system landscape, rounding off the Lumenis portfolio for this application. The scanning technology for the deep fractional application is a direct regeneration of Lumenis’ legendary UltraPulse® DeepFXTM scanner, providing the same spot size and variability in the size, shape, and density of the patterns. In addition to these technology benefits the AcuPulse™ is designed with a state of the art touchscreen user interface and safety control systems to make it an effective, affordable and safe value in the fractional laser market.
To learn more about the AcuPulse™ System, visit www.lumenis.com/acupulse
To learn more about the importance of pulsed laser technology visit www.lumenis.com/checkyourpulse
Lumenis is Israel’s largest medical device company with more than 800 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. For more information about Lumenis and its products, log onto www.lumenis.com.
Director of Corporate Communications
Lumenis® and its logo are trademarks or registered trademarks of the Lumenis Group of Companies.
Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled “Risk Factors”, as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.